{
  "_id": "d6358dd438d8dc8761e8e16d12d72e4a6cdbcd5952ebecbd2cbd357ac509e94a",
  "feed": "wall-street-journal",
  "title": "EXCHANGE --- UnitedHealth Will Drop Some Copays",
  "text": "<p>UnitedHealth announced the initiative during its second-quarter earnings call. The healthcare and health-insurance company on Friday reported profit that beat analysts' expectations, and it raised its earnings guidance for the year.</p><p>In addition to insulin, used by patients with diabetes, and naloxone, which is administered to people suffering the effects of opioid overdoses, the zero-copay list will include epinephrine, administered to curb allergic reactions; glucagon, used to treat hypoglycemia, or low blood sugar; and albuterol, taken to ease breathing difficulties caused by asthma.</p><p>For the second quarter, UnitedHealth said revenue rose 13% to $80.3 billion.</p><p>The company now expects full-year earnings of $20.45 a share to $20.95 a share, up 15 cents on either end from its prior guidance.</p><p>Profit for the quarter ended June 30 came in at $5.07 billion, or $5.34 a share, compared with $4.27 billion, or $4.46 a share, a year earlier.</p><p>License this article from Dow Jones Reprint Service</p>",
  "published": "2022-07-16T00:00:00.000Z",
  "tags": [
    {
      "id": "US91324P1021",
      "nexusId": "10018613",
      "name": "UnitedHealth Group Incorporated",
      "offsets": [
        {
          "start": 13,
          "end": 25
        },
        {
          "start": 0,
          "end": 12
        },
        {
          "start": 617,
          "end": 629
        }
      ]
    }
  ]
}